VLON
Price:
$0.4
Market Cap:
$0
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.[Read more]
Industry
Biotechnology
IPO Date
2021-02-10
Stock Exchange
NASDAQ
Ticker
VLON
According to Vallon Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.03. This represents a change of -99.98% compared to the average of -170.11 of the last 4 quarters.
The mean historical PE Ratio of Vallon Pharmaceuticals, Inc. over the last ten years is -6.49. The current -0.03 PE Ratio has changed -53.76% with respect to the historical average. Over the past ten years (40 quarters), VLON's PE Ratio was at its highest in in the December 2022 quarter at -0.34. The PE Ratio was at its lowest in in the December 2023 quarter at -248.35.
Average
-6.49
Median
-7.14
Minimum
-13.46
Maximum
-0.31
Discovering the peaks and valleys of Vallon Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 33.09%
Maximum Annual PE Ratio = -0.31
Minimum Annual Increase = -90.22%
Minimum Annual PE Ratio = -13.46
Year | PE Ratio | Change |
---|---|---|
2023 | -0.31 | -23.65% |
2022 | -0.41 | -90.22% |
2021 | -4.17 | -60.14% |
2020 | -10.46 | -22.27% |
2019 | -13.46 | 33.09% |
The current PE Ratio of Vallon Pharmaceuticals, Inc. (VLON) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.63
5-year avg
-5.76
10-year avg
-6.49
Vallon Pharmaceuticals, Inc.’s PE Ratio is greater than Ikena Oncology, Inc. (-1.22), greater than Foghorn Therapeutics Inc. (-4.49), greater than Werewolf Therapeutics, Inc. (-1.64), greater than Clene Inc. (-25.01), greater than Immunome, Inc. (-3.09), greater than Zura Bio Limited (-9.00), greater than Phio Pharmaceuticals Corp. (-0.15), greater than Sonnet BioTherapeutics Holdings, Inc. (-0.55), greater than 180 Life Sciences Corp. (-0.14), greater than Cardio Diagnostics Holdings, Inc. (-0.75), greater than Palisade Bio, Inc. (-0.31), greater than Quoin Pharmaceuticals, Ltd. (-0.47), greater than Revelation Biosciences, Inc. (-0.09), greater than Virax Biolabs Group Limited (-1.34), greater than Unicycive Therapeutics, Inc. (-0.46), greater than ContraFect Corporation (-0.11), greater than Allarity Therapeutics, Inc. (-0.19), less than CNS Pharmaceuticals, Inc. (-0.00), greater than Windtree Therapeutics, Inc. (-0.14), greater than Panbela Therapeutics, Inc. (-0.06),
Company | PE Ratio | Market cap |
---|---|---|
-1.22 | $81.56M | |
-4.49 | $416.63M | |
-1.64 | $88.28M | |
-25.01 | $38.37M | |
-3.09 | $813.14M | |
-9.00 | $230.86M | |
-0.15 | $2.25M | |
-0.55 | $4.53M | |
-0.14 | $1.89M | |
-0.75 | $6.94M | |
-0.31 | $4.25M | |
-0.47 | $3.06M | |
-0.09 | $1.43M | |
-1.34 | $15.24M | |
-0.46 | $33.41M | |
-0.11 | $1.72M | |
-0.19 | $7.01M | |
-0.00 | $4.60M | |
-0.14 | $1.66M | |
-0.06 | $1.75M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vallon Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Vallon Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Vallon Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Vallon Pharmaceuticals, Inc. (VLON)?
What is the highest PE Ratio for Vallon Pharmaceuticals, Inc. (VLON)?
What is the 3-year average PE Ratio for Vallon Pharmaceuticals, Inc. (VLON)?
What is the 5-year average PE Ratio for Vallon Pharmaceuticals, Inc. (VLON)?
How does the current PE Ratio for Vallon Pharmaceuticals, Inc. (VLON) compare to its historical average?